Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Tomivosertib |
| Trade Name | |
| Synonyms | eFT508|EFT-508 |
| Drug Descriptions |
Tomivosertib (eFT508) inhibits MNK1/2 and phosphorylation of eIF4E, which may lead to impaired translation of CD274 (PD-L1), potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (PMID: 30643286, PMID: 34012509). |
| DrugClasses | MNK1/2 Inhibitor 3 |
| CAS Registry Number | 1849590-01-7 |
| NCIT ID | C125062 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Avelumab + Tomivosertib | Avelumab Tomivosertib | 0 | 1 |
| Azacitidine + Tomivosertib + Venetoclax | Azacitidine Tomivosertib Venetoclax | 0 | 1 |
| Paclitaxel + Tomivosertib | Paclitaxel Tomivosertib | 0 | 1 |
| Pembrolizumab + Pemetrexed Disodium + Tomivosertib | Pembrolizumab Pemetrexed Disodium Tomivosertib | 0 | 1 |
| Pembrolizumab + Tomivosertib | Pembrolizumab Tomivosertib | 0 | 1 |
| Tomivosertib | Tomivosertib | 0 | 6 |